Dabur India Limited, India's leading natural healthcare company, plans to invest over Rs 250 crore in the next one year to set up a greenfield facility for manufacturing a range of consumer goods and upgrade its existing facilities.

The company plans to set up a new manufacturing facility in India entailing a capital expenditure of about Rs 150 crore, which would be made in the next fiscal.

Besides, the company will undertake another Rs 100 crore of capital expenditure this fiscal at its existing facilities. This unit is expected to manufacture a range of new personal care products.

Further, Dabur also has plans to hike prices of its consumer and healthcare products, keeping in mind the intense inflationary pressure. The company has planed a 7% hike in prices in the consumer care division and 8-10% hike in the consumer health division.

The company had forayed into the skin care market last year with the launch of rose-based skin care products under the 'Gulabari' brand name.

Dabur Pharma has recorded a profit before tax of Rs 17.73 crore for the first quarter ended June 30, an increase of 50% over the profit before tax of Rs 11.82 crore in the corresponding period last year.